Total Payments
$743.85
2024 Payments
$209.71
Companies
20
Transactions
43
Medicare Patients
7,744
Medicare Billing
$4.5M
Payment Breakdown by Category
Food & Beverage$673.89 (90.6%)
Education$69.96 (9.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $673.89 | 37 | 90.6% |
| Education | $69.96 | 6 | 9.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $103.45 | 5 | $0 (2024) |
| Janssen Biotech, Inc. | $86.65 | 4 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $70.02 | 3 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $55.68 | 3 | $0 (2023) |
| PFIZER INC. | $49.28 | 4 | $0 (2023) |
| Mirati Therapeutics, Inc. | $41.13 | 2 | $0 (2024) |
| Seattle Genetics, Inc. | $36.87 | 3 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $34.92 | 2 | $0 (2023) |
| Merck Sharp & Dohme LLC | $33.73 | 2 | $0 (2024) |
| Amgen Inc. | $30.47 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $209.71 | 10 | E.R. Squibb & Sons, L.L.C. ($46.64) |
| 2023 | $202.82 | 10 | Janssen Biotech, Inc. ($50.25) |
| 2022 | $162.17 | 8 | E.R. Squibb & Sons, L.L.C. ($36.11) |
| 2021 | $22.97 | 2 | Gilead Sciences, Inc. ($11.92) |
| 2019 | $24.19 | 2 | Seattle Genetics, Inc. ($12.29) |
| 2018 | $43.10 | 4 | Seattle Genetics, Inc. ($24.58) |
| 2017 | $78.89 | 7 | PFIZER INC. ($33.31) |
All Payment Transactions
43 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/22/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $29.98 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $26.32 | General |
| Category: Oncology | ||||||
| 09/06/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $17.90 | General |
| Category: Oncology | ||||||
| 08/28/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.11 | General |
| 07/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.35 | General |
| Category: Oncology | ||||||
| 05/15/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $21.44 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2024 | Cumberland Pharmaceuticals, Inc. | SANCUSO (Drug) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: ONCOLOGY | ||||||
| 04/25/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: Oncology | ||||||
| 01/11/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.29 | General |
| Category: Oncology | ||||||
| 11/13/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $22.14 | General |
| Category: Oncology | ||||||
| 07/31/2023 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: ONCOLOGY | ||||||
| 07/03/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: Oncology | ||||||
| 06/29/2023 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: Oncology | ||||||
| 04/24/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $13.99 | General |
| Category: ONCOLOGY | ||||||
| 03/17/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $28.65 | General |
| Category: Oncology | ||||||
| 03/06/2023 | Incyte Corporation | PEMAZYRE (Drug), JAKAFI, MONJUVI | Food and Beverage | Cash or cash equivalent | $13.37 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 03/02/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.70 | General |
| Category: Oncology | ||||||
| 02/13/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $23.80 | General |
| Category: ONCOLOGY | ||||||
| 01/16/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2022 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Oncology | ||||||
| 10/03/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: ONCOLOGY | ||||||
| 09/15/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $19.76 | General |
| 08/25/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.35 | General |
| Category: Oncology | ||||||
| 07/06/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $17.99 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 40 | 1,657 | 47,177 | $2.1M | $730,691 |
| 2022 | 41 | 1,725 | 67,219 | $2.6M | $1.1M |
| 2021 | 52 | 2,134 | 78,093 | $3.2M | $1.3M |
| 2020 | 54 | 2,228 | 93,045 | $3.6M | $1.4M |
Total Patients
7,744
Total Services
285,534
Medicare Billing
$4.5M
Procedure Codes
187
All Medicare Procedures & Services
187 procedure records from CMS Medicare Utilization — Page 2 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 32 | 43 | $5,375 | $1,098 | 20.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 29 | 48 | $3,120 | $1,087 | 34.8% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 22 | 32 | $4,000 | $787.59 | 19.7% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 12 | 18 | $2,970 | $779.56 | 26.2% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 20 | 104 | $16,640 | $629.70 | 3.8% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 23 | 620 | $39,680 | $507.81 | 1.3% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 18 | 33 | $1,155 | $329.37 | 28.5% |
| J9045 | Injection, carboplatin, 50 mg | Office | 2023 | 11 | 117 | $11,700 | $231.97 | 2.0% |
| J9190 | Injection, fluorouracil, 500 mg | Office | 2023 | 11 | 102 | $2,550 | $193.24 | 7.6% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 61 | 1,537 | $1,537 | $149.50 | 9.7% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 38 | 57 | $342.00 | $115.15 | 33.7% |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | Office | 2023 | 20 | 370 | $7,928 | $111.41 | 1.4% |
| J3475 | Injection, magnesium sulfate, per 500 mg | Office | 2023 | 16 | 104 | $208.00 | $66.93 | 32.2% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 17 | 25 | $200.00 | $26.80 | 13.4% |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 2023 | 20 | 20 | $120.00 | $20.24 | 16.9% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2022 | 16 | 13,300 | $678,300 | $308,760 | 45.5% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2022 | 15 | 6,000 | $546,000 | $253,799 | 46.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 27 | 7,500 | $187,500 | $124,119 | 66.2% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2022 | 11 | 1,550 | $147,250 | $55,327 | 37.6% |
| Q5120 | Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg | Office | 2022 | 16 | 372 | $249,240 | $49,859 | 20.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 216 | 506 | $101,200 | $47,634 | 47.1% |
| J9041 | Injection, bortezomib (velcade), 0.1 mg | Office | 2022 | 13 | 1,137 | $102,330 | $37,211 | 36.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 128 | 340 | $134,300 | $36,255 | 27.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 318 | 470 | $70,500 | $29,097 | 41.3% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 59 | 170 | $27,200 | $27,144 | 99.8% |
About Dr. Sharon Goble, M.D
Dr. Sharon Goble, M.D is a Hematology & Oncology healthcare provider based in Richmond, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255394417.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sharon Goble, M.D has received a total of $743.85 in payments from pharmaceutical and medical device companies, with $209.71 received in 2024. These payments were reported across 43 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($673.89).
As a Medicare-enrolled provider, Goble has provided services to 7,744 Medicare beneficiaries, totaling 285,534 services with total Medicare billing of $4.5M. Data is available for 4 years (2020–2023), covering 187 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Richmond, VA
- Active Since 04/10/2006
- Last Updated 05/21/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1255394417
Products in Payments
- IMBRUVICA (Drug) $108.83
- OPDIVO (Biological) $83.69
- KRAZATI (Drug) $41.13
- ADCETRIS (Biological) $36.87
- KEYTRUDA (Biological) $33.73
- LUTATHERA (Drug) $29.98
- INLYTA (Drug) $26.86
- Lenvima (Drug) $26.32
- XPOVIO (Drug) $24.57
- KISQALI (Drug) $23.86
- TAGRISSO (Drug) $22.14
- DARZALEX (Biological) $21.60
- EPKINLY (Drug) $21.44
- LUMAKRAS (Drug) $19.37
- PLUVICTO (Drug) $16.18
- SANCUSO (Drug) $13.40
- PEMAZYRE (Drug) $13.37
- IMFINZI (Drug) $12.78
- Erleada (Drug) $11.90
- SUTENT (Drug) $11.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Richmond
Dr. Victor Yazbeck, M.d, M.D
Hematology & Oncology — Payments: $390,374
Hematology & Oncology $390,374
Attique Samdani, M.d, M.D
Hematology & Oncology — Payments: $146,382
Hematology & Oncology $146,382
Dr. Elke Friedman, Md, MD
Hematology & Oncology — Payments: $25,274
Hematology & Oncology $25,274
Dr. Asit Paul, M.d., Ph.d.,, M.D., PH.D.,
Hematology & Oncology — Payments: $7,490
Hematology & Oncology $7,490
Dr. Ghulam Qureshi, M.d, M.D
Hematology & Oncology — Payments: $7,032
Hematology & Oncology $7,032
Gisa-Beate Schunn, M.d, M.D
Hematology & Oncology — Payments: $5,929
Hematology & Oncology $5,929